TYMS and non-small cell lung carcinoma: Pemetrexed, a novel, multi-targeted antifolate chemotherapy agent that inhibits target enzymes (thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase), was initially approved for second-line treatment of advanced NSCLC [32].